ReviewProstate international2026
Is Prostate Imaging Reporting and Data System equally predictive across racial groups? A narrative review of multiparametric magnetic resonance imaging performance in Black versus White men.
Review in Prostate international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiparametric magnetic resonance imaging (mpMRI) has become integral to prostate cancer (PCa) screening, improving detection and reducing unnecessary biopsies. This study investigated radiological disparities in mpMRI between Black and White PCa patients to improve diagnostic equity. Materials and methods: A PubMed literature search was conducted using keywords related to PCa, MRI, and racial disparities. Articles discussing mpMRI outcomes in White and Black PCa patients were selected. Results: From 13 studies, two reported higher Prostate Imaging Reporting and Data System (PI-RADS) 4 and 5 scores among Black patients, while three showed higher proportions in White patients without increased clinically significant prostate cancer (csPCa). csPCa is defined as International Society of Urological Pathology (ISUP) grade group ≥2. The csPCa detection rate in Black patients was equal to or higher than in White patients, with some studies showing more PI-RADS 3 lesions among Black patients with csPCa. Key findings include the following: (1) Development bias: PI-RADS may not account for racial variations; (2) inconsistent lesion detection across racial groups; (3) lower PI-RADS scores may mask clinically relevant cancer in Black patients; and (4) inadequate representation of the disease in Black men. Anatomical variations may affect lesion visibility, requiring dedicated imaging pathology studies. Conclusions: While valuable for PCa detection, current mpMRI applications may contribute to racial disparities and biopsies should not be omitted in black patients with negative mpMRI or PI-RADS 3 lesions. Addressing these disparities requires inclusive research and consideration of racial variations in diagnostic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.